Weijian Ni

6PUBLICATIONS
14CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical infection agents (incl. prions)Surface water quality processes and contaminated sediment assessmentEpigenetics (incl. genome methylation and epigenomics)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 22, 2024
CHOP-mediated Gasdermin E expression promotes pyroptosis, inflammation, and mitochondrial damage in renal ischemia-reperfusion injury.

Nannan Ma, Hao Lu, Ning Li

|Aug 04, 2023
Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2-dependent mechanism.

Wei-Jian Ni, Hong Zhou, Hao Lu

|Oct 05, 2022
RNA N6 -methyladenosine modifications and potential targeted therapeutic strategies in kidney disease.

Wei-Jian Ni, Hao Lu, Nan-Nan Ma

|Apr 13, 2022
Inhibition of METTL3 attenuates renal injury and inflammation by alleviating TAB3 m6A modifications via IGF2BP2-dependent mechanisms.

Jia-Nan Wang, Fang Wang, Jing Ke

|Jan 10, 2022
Berberine regulates mesangial cell proliferation and cell cycle to attenuate diabetic nephropathy through the PI3K/Akt/AS160/GLUT1 signalling pathway.

Wei-Jian Ni, Xi-Mei Guan, Jing Zeng

|May 06, 2020
Potential therapeutic targets and promising drugs for combating SARS-CoV-2.

Hong Zhou, Yan Fang, Tao Xu

Pageof 1

Frequent Collaborators

2 joint publications

Xiao-Ming Meng

1 joint publications

Tao Xu

1 joint publications

Jia-Nan Wang

1 joint publications

Fang Wang